NL-OMON44086已完成不适用
A Phase 1 Study of ABT-767 in BRCA1- or BRCA2-Mutation Carriers with Advanced Solid Tumors and in Subjects with High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer - M10-976
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- AbbVie B.V.
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •* Subject must be * 18 years of age.
- •* Subjects must have histological or cytological confirmation of locally advanced or metastatic
- •solid tumor, and
- •- a documented BRCA1 or BRCA2 mutation, OR
- •- high grade serous ovarian, fallopian tube, or primary peritoneal cancer.
- •* Subject has an Eastern Cooperative Oncology Group (ECOG) Performance status of 0 to 2.
- •* Subjects must have adequate hematologic, renal, and hepatic function as follows:
- •- Bone Marrow: Absolute neutrophil count (ANC * 1,500/mm3 (1.5 × 109/L); Platelets
- •* 100,000/mm3 (100 × 109/L); Hemoglobin * 9.0 g/dL (1.4 mmol/L) (hemoglobin
- •unsupported by transfusion.
- •- Subject has adequate renal function as demonstrated by serum creatinine value of
- •* 1.5 × the upper limit of normal (ULN) and either an estimated creatinine clearance
- •value of * 50 mL/min as determined by the Cockcroft-Gault formula or a creatinine
- •clearance value of * 50 mL/min/1.73 m2 based on a 24-hour urine collections.
- •- Subject has adequate liver function as demonstrated by serum bilirubin * 1.5 × ULN
- •and AST and ALT * 2.5 x ULN. For subjects with liver metastasis, AST and ALT
- •< 5 × the ULN.
- •- PTT must be * 1.5 x ULN and INR < 1.5. Subjects on anticoagulant (such as
- •Coumadin) are allowed on study and will have PTT and INR as determined by the
- •Investigator.
- •* Women of childbearing potential must agree to use adequate contraception prior to study entry,
- •for the duration of the study participation, and for 90 days following completion of therapy.
- •Women of childbearing potential must have a negative serum pregnancy test within 21 days
- •prior to initiation of treatment and a negative urine pregnancy test on the first day of study drug
- •administration. Post-menopausal women must be amenorrheic for at least 12 months to be
- •considered of non-childbearing potential.
- •Expanded Safety Cohort #1: Subjects with BRCA1 or BRCA2 Mutated
- •Advanced Solid Tumor
- •* Histologically or cytologically confirmed malignancy that is metastatic or unresectable and for which standard curative measures or other therapy that may provide clinical benefit do not exist or are no longer effective. Subjects must also have a documented deleterious BRCA1 or BRCA2
- •* Subject must have at least 1 site accessible for acquisition of tumor or cell tissue via percutaneous needle, punch, or excisional biopsy to be eligible for enrollment (e.g., cutaneous or subcutaneous, palpable lymph nodes or lesions safely accessible for biopsy).
- •* Measurable disease, defined as at least 1 unidimensionally measurable lesion on a CT scan as defined by RECIST version 1.1.
- •Expanded Safety Cohort #2: Advanced ovarian cancer, with known germ line mutation of BRCA1 or BRCA2 or no mutation in BRCA1 or BRCA2. .
- •* Histologically or cytologically confirmed malignancy that is metastatic or unresectable and for which standard curative measures or other therapy that may provide clinical benefit do not exist or are no longer effective. Subjects must also have a known status that is either positive or negative for a documented deleterious BRCA1 or BRCA2 mutation
- •* Subjects with ovarian cancer and non-measurable disease with an elevation of serum CA-125 level by Gynecologic Cancer Intergroup (GCIG) criteria (baseline sample that is at least twice the upper limit of normal and within 2 weeks prior to starting treatment) may also be in
排除标准
- •* Expanded cohort only: Subject has previously received a PARP inhibitor.
- •* Subject has received anti-cancer therapy including chemotherapy, immunotherapy,
- •radiotherapy, biologic or any investigational therapy within a period of 28 days or 5 half lives
- •(whichever is shorter) prior to Study Day 1.
- •* Subject has known CNS metastases.
- •* Subject has unresolved toxicities from prior anti-cancer therapy, defined as any Common
- •Terminology Criteria for Adverse Events (CTCAE v 4.0) grade 2 or higher clinically significant
- •toxicity (excluding alopecia).
- •* Subject has had major surgery within 28 days prior to Study Day 1.
- •* Clinically significant uncontrolled condition(s) or any medical condition which in the opinion
- •of the study investigator places the subject at an unacceptably high risk for toxicities.
- •* Psychiatric illness/social situation that would limit compliance with study requirements.
- •* Lactating or pregnant female.
研究者
相似试验
已完成
1 期
Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal CancerFallopian TubePrimary Peritoneal CancerSolid Tumors (e.g. Breast, Ovarian, Prostate, or Pancreatic) and OvarianNCT01339650AbbVie (prior sponsor, Abbott)93
进行中（未招募）
1 期
Phase II study aiming at evaluating activity of Yondelis in recurrent ovarian cancer patients with BRCA mutatioadvaced ovarian cancerMedDRA version: 14.1Level: HLTClassification code 10033129Term: Ovarian neoplasms malignant (excl germ cell)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-001298-17-ITPOLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
进行中（未招募）
不适用
A Phase II Study of MK-0457 in Patients With BCR-ABL T315I Mutant Chronic Myelogenous Leukemia and Philadelphia Chromosome-positive Acute Lymphoblastic LeukemiaCML and Ph+ALLMedDRA version: 8.1Level: LLTClassification code 10000845Term: Acute lymphoblastic leukemiaEUCTR2006-004535-30-PTMerck Sharp & Dohme, Lda.272
进行中（未招募）
1 期
A Phase II Study of MK-0457 in Patients With BCR-ABL T315I Mutant Chronic Myelogenous Leukemia and Philadelphia Chromosome-positive Acute Lymphoblastic LeukemiaCML and Ph+ALLMedDRA version: 8.1 Level: LLT Classification code 10000845 Term: Acute lymphoblastic leukemiaEUCTR2006-004535-30-DKMerck & Co., Inc.3
进行中（未招募）
不适用
A Phase II Study of MK-0457 in Patients With BCR-ABL T315I Mutant Chronic Myelogenous Leukemia and Philadelphia Chromosome-positive Acute Lymphoblastic LeukemiaCML and Ph+ALLMedDRA version: 8.1Level: LLTClassification code 10000845Term: Acute lymphoblastic leukemiaMedDRA version: 9.1Level: LLTClassification code 10009012Term: Chronic myelogenous leukemiaEUCTR2006-004535-30-DEMerck & Co., Inc.272